Posted by Michael Wonder on 09 Jul 2025
New Wegovy dose submitted to EMA for approval, with 1 in 3 trial participants achieving 25% or more weight loss
8 July 2025 - Novo Nordisk today announced the submission of an application to the EMA for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg).
This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity, as part of their journey towards better health.
